Polypharmacy and Potential Drug Interactions in Hemodialysis Patients at Hospital X
Bilah Samping Artikel
hemodialysis,
polypharmacy,
potential drug–drug interactions,
medication safety penyakit ginjal kronis,
hemodialisis,
polifarmasi,
potensi interaksi obat,
keamanan pengobatan
Isi Artikel Utama
Abstrak
Chronic kidney disease (CKD) patients undergoing hemodialysis frequently receive multiple medications to manage renal complications and comorbidities, increasing the risk of polypharmacy and potential drug–drug interactions (pDDIs), which may compromise treatment safety and effectiveness. This study aimed to analyze the association between polypharmacy and the occurrence of pDDIs among CKD patients undergoing hemodialysis at Hospital X. A retrospective analytical cross-sectional study was conducted using medical records of 110 CKD patients undergoing hemodialysis between February and April 2026. Potential drug–drug interactions were identified using the Medscape Drug Interaction Checker. Data were analyzed descriptively, while the associations between polypharmacy, age, sex, comorbidity status, and pDDIs were evaluated using the Chi-square test or Fisher's Exact Test, with a significance level of p<0.05. Polypharmacy was identified in 71.8% of patients, while hyperpolypharmacy occurred in 24.5%. Potential drug–drug interactions were detected in 91.8% of patients, with 387 interaction events identified. Pharmacodynamic interactions accounted for 56.6% of all interactions, and Monitor Closely was the most common severity category (55.6%). Fisher's Exact Test demonstrated a significant association between polypharmacy and pDDIs (p<0.001), whereas age (p=0.159), sex (p=1.000), and comorbidity status (p=0.222) were not significantly associated with pDDIs. These findings indicate that increasing medication burden substantially elevates the risk of potential drug–drug interactions in hemodialysis patients, highlighting the importance of routine medication review and clinical pharmacist involvement to optimize pharmacotherapy and improve patient safety.
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.
Referensi
Al-Khulaifi, A., Khatib, M., Ali, E., Ali, M. Y., & Danjuma, M. I.-M. (2023). What is Polypharmacy in Patients with Chronic Kidney Disease? A Systematic Review. Clinical Therapeutics, 45(11), e217–e221. https://doi.org/10.1016/j.clinthera.2023.08.007
Carolina, A., Wibowo, P., & Prameswari, R. (2024). Characteristics of Chronic Kidney Disease Patients Undergoing Hemodialysis at RSPAL Dr. Ramelan Surabaya from January to June 2022. Journal of Health Sciences, 17(03), 225–237. https://doi.org/10.33086/jhs.v17i03.4599
Chertow, G. M., Plumb, T. J., & Post, J. B. (2023). Multimorbidities and pill burden in patients on maintenance hemodialysis. Journal of Nephrology & Clinical Therapeutics, 18(2), 115–125.
DiPiro, J. T., Yee, G. C., Haines, S. T., Nolin, T. D., Ellingrod, V. L., & Posey, L. M. (2023). DiPiro’s pharmacotherapy: A pathophysiologic approach (12th ed.). McGraw Hill.
Febriyani, G., & Padmasari, S. (2024). Analysis of the Relationship between Polypharmacy and Antihypertensive Drug Interactions in Chronic Kidney Failure Patients with Hemodialysis at Sleman Regional Hospital, Yogyakarta. JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X, 16(2), 177–186. https://doi.org/10.35617/jfionline.v16i2.231
Galistiani, G. F., Ratri, E. P., & Wahyono, D. (2025). Polifarmasi dan Interaksi Obat pada Pasien Gagal Ginjal Kronis yang Menjalani Hemodialisa. PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia), 55–59. https://doi.org/10.30595/pharmacy.v22i1.26887
Hidayangsih, P. S., Tjandrarini, D. H., Sukoco, N. E. W., Sitorus, N., Dharmayanti, I., & Ahmadi, F. (2023). Chronic kidney disease in Indonesia: evidence from a national health survey. Osong Public Health and Research Perspectives, 14(1), 23–30. https://doi.org/10.24171/j.phrp.2022.0290
Huri, H. Z., & Ling, L. C. (2013). Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia. BMC Public Health, 13(1), 1192. https://doi.org/10.1186/1471-2458-13-1192
Hustrini, N. M., Susalit, E., Harimurti, K., Haryoso, I. S., Legrans, A. E., Damarjati, K., Minangsih, S., Nurhisan, L., Zaini, M., Oktavianti, S., Pratiwi, S., Pradesa, M. G., Anthony, G., Sari, D. Wi. R., Purnama, R. C., Puspitasari, W. R. M., Rajagukguk, M. J., van Diepen, M., & Rotmans, J. (2025). Prevalence, incidence and risk factors of chronic kidney disease in people with diabetes and hypertension, and the prognosis and kidney function decline in Indonesia: a multicentre cross-sectional study in primary care centres. BMJ Open, 15(10), e103779. https://doi.org/10.1136/bmjopen-2025-103779
Kementerian Kesehatan Republik Indonesia. (2023). Survei Kesehatan Indonesia.
Kheshti, R., Aalipour, M., & Namazi, S. (2016). A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. Journal of Research in Pharmacy Practice, 5(4), 257. https://doi.org/10.4103/2279-042X.192461
Mark, P. B., Stafford, L. K., Grams, M. E., Aalruz, H., Abd ElHafeez, S., Abdelgalil, A. A., Abdulkader, R. S., Abeywickrama, H. M., Abiodun, O. O., Abramov, D., Abrar, M. M., Abreu, L. G., Abubakar, B., Aburuz, S., Addo, I. Y., Adegboye, O. A., Adegoke, N. A., Adeyeoluwa, T. E., Adnani, Q. E. S., … Coresh, J. (2025). Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 406(10518), 2461–2482. https://doi.org/10.1016/S0140-6736(25)01853-7
Matzke, G. R., Aronoff, G. R., Atkinson, A. J., Bennett, W. M., Decker, B. S., Eckardt, K.-U., Golper, T., Grabe, D. W., Kasiske, B., Keller, F., Kielstein, J. T., Mehta, R., Mueller, B. A., Pasko, D. A., Schaefer, F., Sica, D. A., Inker, L. A., Umans, J. G., & Murray, P. (2011). Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 80(11), 1122–1137. https://doi.org/10.1038/ki.2011.322
Patel, D., Bertz, R., Ren, S., Boulton, D. W., & Någård, M. (2020). A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug–Drug Interactions with Orally Administered Medications. Clinical Pharmacokinetics, 59(4), 447–462. https://doi.org/10.1007/s40262-019-00844-3
Pramitaningastuti, A. (2024). Overview of Polypharmacy and Drug Interactions in Chronic Kidney Disease Patients at Siloam Hospitals Lippo Village. Media Farmasi Indonesia, 19(1), 74–80. https://doi.org/10.53359/mfi.v19i1.271
Rahman, S., & Santika, K. (2022). Causative Factors of Chronic Kidney Disease in Patiens with Hemodialysis Therapy. Jurnal Kesehatan Masyarakat, 18(1), 114–121. https://doi.org/10.15294/kemas.v18i1.28307
Rama, M., Viswanathan, G., & Kumar, S. (2021). Clinical pharmacy interventions and medication reconciliation in end-stage renal disease. International Journal of Clinical Pharmacy, 43(4), 982–990.
Ratnasari, P. M. D., Dhrik, M., Rizqy, L. K. R., & Devi, N. K. D. R. (2024). Evaluasi Kesesuaian Dosis dan Interaksi Obat Potensial pada Pasien Gagal Ginjal Kronik di Rumah Sakit Swasta Denpasar Bali. Jurnal Ilmiah Medicamento, 10(2), 109–123. https://doi.org/10.36733/medicamento.v10i2.9143
Sari, O. M. (2025). Identification of Potential Drug Interactions of Patients with Chronic Kidney Disease Based on Lexicomp® Application. Jurnal Ilmu Farmasi Dan Farmasi Klinik, 22(1). https://doi.org/10.31942/jiffk.v22i1.11713
Souza dos Santos, N. J., Brasileiro Lemos, L., Ribeiro Fernandes Almeida, P. H., Alves Nery, A., & Da Silveira Lemos, G. (2018). Interações medicamentosas potenciais em medicamentos prescritos e não prescritos para pacientes hemodialíticos. O Mundo Da Saúde, 42(4), 845–872. https://doi.org/10.15343/0104-7809.20184204845872
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., Lamb, E., Lin, P., Madero, M., McIntyre, N., Morrow, K., Roberts, G., Sabanayagam, D., Schaeffner, E., Shlipak, M., … Levin, A. (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 105(4), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
Tatro, D. S. (2014). Drug interaction facts: The authority on drug interactions. Wolters Kluwer Health.
Verbeeck, R. K., & Musuamba, F. T. (2009). Pharmacokinetics and dosage adjustment in patients with renal dysfunction. European Journal of Clinical Pharmacology, 65(8), 757–773. https://doi.org/10.1007/s00228-009-0678-8